Filtered By:
Specialty: Drugs & Pharmacology
Condition: Anxiety

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 98 results found since Jan 2013.

Characteristics of traditional Chinese medicine usage in patients with stroke in Taiwan: A nationwide population-based study
Conclusion Adjunctive TCM use may reduce the risk of mortality rate among stroke patients. Bu-yang-huan-wu-tang and Dan-shen are the most common prescribed Chinese herbal formula and single herb for stroke patients, respectively. Future study investigating the anti-inflammatory and neuroprotective efficacy of Bu-yang-huan-wu-tang and Dan-shen in stroke is warranted. Graphical abstract
Source: Journal of Ethnopharmacology - April 22, 2016 Category: Drugs & Pharmacology Source Type: research

Title: The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach.
Abstract Post-stroke depression (PSD) is a common and serious complication following stroke. Both stroke and depression have independently been associated with pathologically elevated glutamate levels in the brain's extra-cerebral fluid (ECF). Here we evaluate an alternative therapeutic approach to PSD with pyruvate. Rats were randomly assigned into one of 3 groups: Middle Cerebral Artery Occlusion (MCAO) plus pyruvate treatment, MCAO plus placebo treatment, and sham operated rats. Post-MCAO depressive and anxiety-like behavior was assessed, along with neurological status, brain infarct zone, brain edema, blood br...
Source: Neuropharmacology - May 29, 2019 Category: Drugs & Pharmacology Authors: Frank D, Kuts R, Tsenter P, Gruenbaum BF, Grinshpun Y, Zvenigorodsky V, Shelef I, Natanel D, Brotfain E, Zlotnik A, Boyko M Tags: Neuropharmacology Source Type: research

L-proline transporter inhibitor (LQFM215) promotes neuroprotection in ischemic stroke
CONCLUSIONS: This dataset suggests that the new compounds inhibit cerebral L-proline uptake and that LQFM215 promotes neuroprotection and neuro-repair in the acute ischemic stroke model.PMID:36719635 | DOI:10.1007/s43440-023-00451-x
Source: Pharmacological Reports - January 31, 2023 Category: Drugs & Pharmacology Authors: Gustavo Almeida Carvalho Raphaela Almeida Chiareli Bruno Lemes Marques Ricardo Cambraia Parreira Eric de Souza Gil Fl ávio Silva de Carvalho Andr é Luís Batista da Rocha Rafaela Ribeiro Silva Fran çois Noël Boniek Gontijo Vaz Luciano Morais Li ão Sh Source Type: research

The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials
ConclusionFluoxetine improved FMMS and reduced anxiety and depression. More well-designed and large sample-size RCTs are required to further analyze the efficacy of fluoxetine in post-stroke recovery.
Source: International Journal of Clinical Pharmacy - April 20, 2023 Category: Drugs & Pharmacology Source Type: research

Esketamine ameliorates post-stroke anxiety by modulating microglial HDAC3/NF- κB/COX1 inflammatory signaling in ischemic cortex
In conclusion, this study suggests esketamine could alleviate microglial activation, reduces inflammatory cytokine, and inhibits the expression of HDAC3 and NF-κB in the cortex of PSA mice to attenuate anxiety-like behavior. Our results provided a new potential therapeutic target for applying esketamine to PSA.PMID:36997050 | DOI:10.1016/j.ejphar.2023.175667
Source: European Journal of Pharmacology - March 30, 2023 Category: Drugs & Pharmacology Authors: Ailin Huang Yang Chen Shaoshuang Wang Hailiang Du Ao Guan Huanghui Wu Qian Zhai Na Duan Xuying Li Pin Zhao Yulin Zhu Juan Bai Ye Xiao Tingting Yang Qiang Wang Bin Deng Source Type: research

Patient ‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke
ConclusionsOur findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - November 30, 2016 Category: Drugs & Pharmacology Authors: Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Vasil Hricak, Jan Murin, Peter Kukumberg, Tomas Tesar, Adam Hloska, Rashmi Shah Tags: Original Report Source Type: research

Cilostazol for treatment of cerebral infarction.
Authors: Noma K, Higashi Y Abstract INTRODUCTION: Stroke not only causes critical disability and death but is also a cause of anxiety with the possibility of secondary cardiovascular events including secondary ischemic stroke. Indeed, patients with a history of previous stroke have a high rate of stroke recurrence, indicating the clinical importance of secondary stroke prevention. Area of covered: This review provides an overview of the pooled evidence for cilostazol's use in the management of secondary stroke prevention. Among the various antiplatelet agents that are available, aspirin is the most frequently used ...
Source: Expert Opinion on Pharmacotherapy - September 14, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome 
.
We present a unique case of synchronous rhabdomyolysis and Ogilvie's syndrome in an 80-year-old lung cancer survivor following a recent ischemic stroke for which she was prescribed clopidogrel and rosuvastatin for secondary prevention, and maprotiline for post-stroke, new-onset insomnia and anxiety. The ADRs resolved on removal of the offending agents and initiation of conservative treatment. Retrospective pharmacogenetic testing of the patient's drug-metabolizing enzymes and transporters was performed to guide further management and prevent future potential drug interactions and ADRs. What is novel and conclusions: This i...
Source: International Journal of Clinical Pharmacology and Therapeutics - March 5, 2017 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Hippocampal Endothelin-1 decreases excitability of pyramidal neurons and produces anxiolytic effects.
Abstract Anxiety disorders contribute to the pathophysiology of psychiatric diseases, including major depression, substance abuse, and schizophrenia. The hippocampus is important for anxiety modulation. However, the mechanisms that control the neuronal activity of the hippocampus in anxiety are still not clear. We found that Endothelin-1 (ET1) mRNA in the hippocampus was down-regulated in high-anxiety mice. Neutralizing endogenous ET1 in the hippocampal CA1 enhanced anxiety-like behaviors. We next revealed that most expression of ET1 and its receptors in the CA1 takes place in pyramidal neurons, and the ET1 signal...
Source: Neuropharmacology - March 12, 2017 Category: Drugs & Pharmacology Authors: Chen M, Shu S, Yan HH, Pei L, Wang ZF, Wan Q, Bi LL Tags: Neuropharmacology Source Type: research

Recombinant tissue plasminogen activator induces long-term anxiety-like behaviors via the ERK1/2-GAD1-GABA cascade in the hippocampus of a rat model.
CONCLUSIONS: RtPA can induce long-term anxiety-like behaviors after a clinical injected dose. The underlying pathogenesis involves the ERK1/2-GAD1-GABA cascade in the hippocampus. This pharmacological side effect of rtPA may further exacerbate post-stroke anxiety disorder for stroke patients. PMID: 28986280 [PubMed - as supplied by publisher]
Source: Neuropharmacology - October 3, 2017 Category: Drugs & Pharmacology Authors: Dong MX, Li CM, Shen P, Hu QC, Wei YD, Ren YF, Yu J, Gui SW, Liu YY, Pan JX, Xie P Tags: Neuropharmacology Source Type: research

The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety.
Abstract The activation of Group II metabotropic glutamate 2/3 (mGlu2/3) receptors reduces the excessive glutamate release that is hypothesized to be associated with neurodegenerative and psychiatric disorders. LY379268 is a highly potent mGlu2/3 receptor agonist that has shown efficacy in several animal models of stroke, epilepsy, drug abuse, schizophrenia, and pain. The present study investigated the effects of LY379268 on anxiety-like behavior in rats assessed in the light/dark and open field tests. The effects of LY379268 on motility in a locomotor activity chamber were also investigated in rats. Administratio...
Source: European Journal of Pharmacology - June 11, 2013 Category: Drugs & Pharmacology Authors: Grivas V, Markou A, Pitsikas N Tags: Eur J Pharmacol Source Type: research

Neuroinflammation, Microglia and Mast Cells in the Pathophysiology of Neurocognitive Disorders: A Review.
Abstract Cells of the immune system and the central nervous system are capable of interacting with each other. The former cell populations respond to infection, tissue injury and trauma by releasing substances capable of provoking an inflammatory reaction. Inflammation is a key element in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury, and neuropsychiatric disorders such as anxiety/depression and schizophrenia. Neuroinflammation may also raise the brain's sensitivity to stress, resulting in stress-related neuropsychiatric disorders, such as anxiety or depression. The cytok...
Source: CNS and Neurological Disorders Drug Targets - November 30, 2014 Category: Drugs & Pharmacology Authors: Skaper SD, Facci L, Giusti P Tags: CNS Neurol Disord Drug Targets Source Type: research